Blinatumomab is a bispecific T-cell engager antibody construct targeting CD19 on B-cell lymphoblasts. We evaluated the safety, pharmacokinetics, recommended dosage, and potential for efficacy of blinatumomab in children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL).
INTRODUCTION
Acute lymphoblastic leukemia (ALL) is the most common malignant disease in children, with an annual incidence of approximately three cases per 100,000 persons. 1 When treated with contemporary combination chemotherapy, approximately 15% of patients relapse and 10% die.
2, 3 Patients who relapse have a cure rate ranging from 10% to 70%, mainly depending on site of and time to relapse. 4, 5 Children with second or greater relapse or refractory disease have a dismal prognosis even when treated with intensive combination chemotherapy and allogeneic hematopoietic stem-cell transplantation (alloHSCT). 6, 7 Targeted treatments are needed to overcome disease resistance and to replace nonspecific toxic chemotherapy, even in children with chemosensitive ALL. Immunotherapy constitutes an important new antileukemic treatment strategy.
CD19 is expressed on B-lineage cells 8, 9 and is a therapeutic target for B-cell precursor ALL (BCP-ALL). 10 Blinatumomab is a bispecific T-cell engager (BiTE) antibody construct that directs CD3-positive effector memory T cells to CD19-positive target cells, triggering cell death. 11, 12 In a large phase II study in adults with relapsed/refractory BCP-ALL, the response rate after single-agent blinatumomab treatment was 43%. 13 We report the results of an international phase I/II study of immunotherapy blinatumomab in children and adolescents with BCP-ALL that was refractory, in second overt relapse, and/or in relapse after alloHSCT.
METHODS

Patients
We conducted an open-label, single-arm phase I/II study at 26 European and US centers. Eligible patients were , 18 years of age (2 to 17 years of age in phase I dosage escalation) and had BCP-ALL with . 25% bone marrow blasts. The disease was primary refractory, in first relapse after full salvage induction regimen, in second or later relapse, or in any 2 /d), we treated additional patients to further assess pharmacokinetics and safety across three age groups (7 to 17 years; 2 to 6 years; , 2 years) before beginning phase II (Appendix Fig A1,  online only) .
Patients received blinatumomab as a 4-week continuous intravenous infusion, followed by a 2-week treatment-free interval. For stepwise dosing (5/15 or 15/30 mg/m 2 /d), the lower dose was administered for the first week of the first cycle followed by the higher dose for the remaining 3 weeks and subsequent cycles. Infusion was administered in the hospital during week 1 of cycle 1 and during the first 2 days of cycle 2, and in an outpatient setting thereafter. Patients achieving complete remission (CR) within the first two cycles could receive up to three additional cycles or be withdrawn from treatment to receive consolidation chemotherapy or HSCT per the investigator's choice. To prevent cytokine-release syndrome (CRS), dexamethasone or hydroxyurea for 4 days was recommended during the first treatment week and was required if baseline bone marrow blasts were . 50%. Patients received prophylactic dexamethasone 10 mg/m 2 6 to 12 hours before and 5 mg/m 2 within 30 minutes of each infusion start. CNS prophylaxis according to institutional/national standards was administered at age-adjusted doses before treatment, at day 15 of cycle 1, and at the day 29 bone marrow assessment. Neurologic events were treated with dexamethasone at 0.2 to 0.4 mg/kg/d (maximum, 24 mg/d) for up to 3 days.
Patients discontinued treatment permanently if they experienced adverse events (AEs) meeting the criteria for dose-limiting toxicities (DLT; Data Supplement), irrespective of their timing; a neurologic event requiring . 1 week to resolve to grade # 1; disease progression or hematologic/extramedullary relapse; or treatment interruption/delay of . 2 weeks or more than two discontinuations for AEs during one cycle. For other blinatumomab-related AEs not meeting DLT criteria but requiring infusion interruption, treatment could be restarted one dosage level lower after resolution to grade # 1.
Bone marrow aspiration (and/or biopsy) for response assessment was performed during screening, at day 15 of cycle 1, and at the end of each 28-day cycle. Hematologic responses were assessed locally and were confirmed by central reference laboratory. CR was defined as no evidence of circulating blasts or extramedullary disease and , 5% blasts in bone marrow (M1). CR was subclassified on the basis of recovery of peripheral blood counts. Minimal residual disease (MRD) response was assessed by central laboratories; data presented are based on flow cytometry. MRD response was defined as , 10 24 detectable blasts; complete MRD response was defined as no detectable blasts. All AEs occurring from treatment start until 30 days after the last infusion were recorded and graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03.
14 Anti-blinatumomab antibodies were assessed.
End Points
The primary phase I end point was the maximum-tolerated dosage (MTD), the maximal dosage at which one or fewer of six patients experienced a DLT. Secondary end points included pharmacokinetics and AE incidence. The primary phase II end point was the CR rate within the first two cycles. Secondary end points included AE incidence, proportion of patients undergoing alloHSCT after blinatumomab treatment, relapse-free survival (RFS), and overall survival (OS). MRD response and complete MRD response were exploratory end points in both phases.
Statistical Analysis
Phase I followed a rolling six design. 15 The phase II sample size was based on a Simon-like two-stage design. 16 A minimum of 40 patients (first stage, n = 21; second stage, n = 19) was estimated to be needed to provide 80% power to test the null hypothesis, with two-sided a = 0.05, that achievement of CR within the first two cycles was # 10% versus the alternative hypothesis of 27.5%. The proportion of responders with exact †Eight patients with MLL translocations were , 2 years old: six had MLL with the fusion partner AF4.t(4;11); two had other MLL abnormalities.
95% CIs was calculated. RFS and OS (time from enrollment to first relapse or death, respectively) were estimated using the Kaplan-Meier method. We conducted separate primary analyses for both study phases (Data Supplement). Pooled analysis of data from patients who received the recommended dosage in phases I or II was exploratory. Efficacy/safety analyses were based on the full-analysis set (all patients who received any blinatumomab infusion). Pharmacokinetic parameters were estimated using noncompartmental methods with Phoenix WinNonlin version 6.3 software on Citrix (Pharsight, St. Louis, MO).
RESULTS
Patient Characteristics
Between January 30, 2012, and June 3, 2014, we treated 49 patients in phase I and 44 patients in phase II (Fig 1) . Patients were considered very high risk on the basis of baseline tumor load, multiple prior relapses, short interval between latest treatment and start of blinatumomab, previous alloHSCT, and/or cytogenetic profile. Most patients were refractory to their last treatment (Table 1) . At the date of study completion (May 24, 2016), all patients had completed the 2-year follow-up, had withdrawn from study, or had died. . This patient experienced febrile neutropenia and pneumonia shortly before infusion start. Thus, the MTD was determined to be 15 mg/m 2 /d. Across dosage cohorts, the incidence of AEs not considered DLTs was also dosage dependent (Data Supplement). Considering the MTD and overall toxicity profile, and to reduce the risk of CRS, the independent DSMB recommended the stepwise dosage of 5/15 mg/m 2 /d for further evaluation.
Twenty-six patients in three age groups (those , 2 years old were enrolled last) were then assessed at 5/15 mg/m 2 /d in the phase I pharmacokinetic expansion. Blinatumomab had approximately linear pharmacokinetics. Steady-state concentration was similar at a given dosage across age groups and was similar to adult reference data (Data Supplement). Although DLTs were not collected formally in the pharmacokinetic expansion, no AEs that Abbreviations: alloHSCT, allogeneic hematopoietic stem-cell transplantation; CR, complete remission; HSCT, hematopoietic stem-cell transplantation; MRD, minimal residual disease; NA, not applicable; NE, not evaluated.
*All patients treated at 5/15 mg/m 2 /d in phase I or II. †Patients died (n = 5) or withdrew consent (n = 1) before the first response assessment. ‡Relapse during the efficacy follow-up (no chemotherapy or alloHSCT between end of blinatumomab treatment and relapse). §Calculated from the date of alloHSCT for all patients who received only blinatumomab at the recommended dose. Not calculated for the other two patient groups because of limited sample size. kPatients who were refractory to blinatumomab but who received subsequent treatments and then proceeded to alloHSCT.
occurred would have met the definition of a DLT. The nature and incidence of AEs were consistent with previous blinatumomab experience (Data Supplement). After review of the toxicity data, the DSMB confirmed 5/15 mg/m 2 /d as the recommended dosage for phase II.
In phase I, seven of 23 patients (30%) in the dosage-escalation part achieved CR within the first two cycles, with all responders achieving a complete MRD response (Data Supplement). Responses were observed at all dosage levels.
Efficacy at the Recommended Dosage
On the basis of the primary analysis (January 12, 2015), 14 of 44 patients (32%; 95% CI, 19% to 48%) in phase II who received the recommended dosage of 5/15 mg/m 2 /d achieved CR within the first two cycles (Table 2) . Overall, 70 patients received this dosage in phase I (n = 26) or phase II (n = 44). Twenty-seven patients (39%; 95% CI, 27% to 51%) achieved CR within the first two cycles (Table 2) , 20 (74%) within cycle 1 and eight of those (30%) by day 15 of cycle 1. At the day 15 assessment, three patients who ultimately responded still had M3 marrow, two had M2 marrow; all other responders had either hypocellular or M1 marrow.
Prespecified analyses showed that CRs had been achieved across subgroups (Fig 2) . The CR rate was 56% among patients with , 50% bone marrow blasts at baseline versus 33% among those with $ 50% blasts. Two of three Ph-positive patients and one of four patients with hypodiploidy achieved CR (Data Supplement). One of two patients with constitutional trisomy 21 had partial remission. Among 10 patients , 2 years of age (eight with MLL translocations), six (60%) achieved CR (including five with MLL translocations; Data Supplement), with four (40%) proceeding to alloHSCT in remission. Of the 27 responders treated with blinatumomab 5/15 mg/m 2 /d, four were still in remission at the end of the 2-year follow-up, two had relapsed but were still alive, three had withdrawn consent (one patient in CR and two after relapse), three had died in CR after alloHSCT, and 15 had relapsed and died (four with a CD19-negative clone).
Fourteen of 27 responders (52%) had a complete MRD response, 13 (48%) by day 15 of cycle 1. Complete MRD response rates were similar across subgroups, with different peripheral counts at response assessment (Data Supplement). Thirteen of the 27 patients (48%) received alloHSCT in blinatumomabinduced remission (seven of whom had received alloHSCT previously).
Forty-three patients did not achieve CR within the first two cycles. At the end of the 2-year follow-up, eight were still alive. Eleven nonresponders received postblinatumomab alloHSCT. Mean cumulative prophylaxis and treatment dexamethasone dose did not differ between responders and nonresponders (72.4 mg/m 2 v 76.3, respectively).
Median RFS was 4.4 months (95% CI, 2.3 to 7.6 months) among patients receiving the recommended dosage who achieved CR, with a median follow-up of 23.1 months (Fig 3A) . The RFS rate at 6 months was 42%. Median RFS was longer for patients with a complete MRD response (7.3 months; 95% CI, 2.7 to 16.4 months; n = 14) than for those without (1.9 months; 95% CI, 0.8 to 6.0 months; n = 12; Fig 3B) . Median OS for all 70 patients was 7.5 months (95% CI, 4.0 to 11.8 months) with a median follow-up of 23.8 months (Fig 3C) .
AEs at the Recommended Dosage
Among the 70 patients who received blinatumomab 5/15 mg/m 2 /d, the most common AEs, regardless of causality, were pyrexia (80%), anemia (41%), nausea (33%), and headache (30%; www.jco.org Data Supplement). Grade 3 and 4 AEs were primarily cytopenias (Table 3) . Most AEs occurred in the first few days of cycle 1 (data not shown). Six of 70 patients had fatal AEs; three died after alloHSCT after blinatumomab-induced remission (Table 3) . Ten patients (14%) interrupted treatment and four (6%) discontinued treatment permanently because of AEs (Data Supplement). Two permanent discontinuations were considered treatment related (grade 3 and 4 CRS). No patient developed anti-blinatumomab antibodies during the study.
Eight (11%) of the 70 patients treated with 5/15 mg/m 2 /d had CRS of any grade (Data Supplement). Three patients had grade 3 and one patient had grade 4 CRS. All four patients interrupted treatment (n = 2) or discontinued treatment permanently (n = 2; after 3 days [cycle 1] and 10 days [cycle 2] of infusion, respectively). All four patients achieved CR at response assessment. Peak levels of interleukin-10, interleukin-6, and interferon-g were higher in patients with CRS than in patients without, although sample sizes were small (Data Supplement). Seventeen (24%) of the 70 patients had neurologic/psychiatric events, mostly tremor (n = 4, 6%), dizziness (n = 3, 4%), and somnolence (n = 3, 4%), regardless of relation to treatment (Data Supplement). Three patients (4%) experienced grade 3 neurologic events: somnolence (two patients) and neuralgia (one patient). Somnolence was a symptom of CRS in one patient and was associated with stroke in the other. There were no grade 4 or 5 neurologic events, but one patient had a grade 4 psychiatric event of confusion. The patient, who failed to respond to blinatumomab, stopped treatment after cycle 1 and developed disease progression. Seventeen days after treatment stop, the patient experienced sepsis with grade 4 confusion and intracranial hemorrhage. In nine patients (13%), neurologic events, primarily tremor and dizziness, were considered to be treatment related. All of these events were of grade 2 and resolved. Two patients interrupted treatment because of grade 2 seizures. There were no permanent discontinuations caused by neurologic events.
Twenty-two of 70 patients treated with 5/15 mg/m 2 /d (31%) had elevated liver function parameters, including ALT (n = 13, 19%), AST (n = 10, 14%), and blood bilirubin (n = 4, 6%). Elevations were seen during the first week of infusion and were transient, typically returning to baseline values within the first cycle. Increases in transaminases were observed without clinical symptoms/signs of hepatic toxicity (data not shown).
DISCUSSION
We established a stepwise blinatumomab dosage of 5 mg/m 2 /d for 1 week, followed by escalation to 15 mg/m 2 /d for the remaining infusion days, as the recommended dosage in children with relapsed/ refractory BCP-ALL, which is similar to the equivalent recommended dosage in adults. 18, 19 Among patients receiving 5/15 mg/m 2 /d, 39% achieved CR within the first two cycles, with most responders achieving complete MRD response. Blinatumomab showed antileukemic activity across all age groups, including patients , 2 years old and those with unfavorable cytogenetics. Given the heavily pretreated population, we consider the CR rate to be clinically satisfactory, particularly in light of the observed toxicities. The few available reports on outcomes in comparable patient groups receiving conventional treatments have described dismal results. Most studies have reported low cytologic CR rates, with as few as 17% of patients with refractory first relapse achieving CR. 6, 7 Our data show CR rates of 30% in patients with refractory ALL and 48% in those with relapse not refractory to the last prior chemotherapy regimen. Furthermore, our cohort had particularly unfavorable characteristics: . 70% of patients had relapsed within 6 months of the previous treatment attempt.
Three of five DLTs in the dosage-finding phase were CRS, which was mitigated subsequently by administering a stepwise blinatumomab dosage. Neurologic events, frequently observed in adult patients receiving blinatumomab, 13, [18] [19] [20] were rare in our pediatric cohort. Most of the grade $ 3 AEs were cytopenias and blood chemistry changes, attributable in part to the underlying leukemia and heavy pretreatment. After managing fever and hypotension during the critical first 3 days of the initial cycle, patients could be treated on an outpatient basis. All fatal AEs not considered DLTs occurred after blinatumomab infusion was stopped and other treatments, including alloHSCT or intensive chemotherapy, were administered; therefore, they were not considered related to blinatumomab.
In a recent large study of blinatumomab in adults with MRDpositive BCP-ALL, 21 rates of CRS were low, suggesting that CRS was related to tumor burden. The results of our study, which required . 25% bone marrow blasts at baseline, support that hypothesis. In contrast, an earlier study in adults with MRDpositive disease reported higher incidences of neurologic events than those seen in our pediatric study. 16, 17 This finding may be related to a low CD19-positive target burden in blood or bone marrow, possibly revealing a higher probability of drug activity beyond the blood-brain barrier. 18, 20, 22 Retrospective analyses in adult relapsed/refractory ALL showed that lower leukemia burden (, 50% bone marrow blasts at baseline) was associated with better CR rates. 19 We noted a similar trend in our population. These data suggest further investigation of blinatumomab, using a higher starting dosage of 15 mg/m 2 /d, in children with BCP-ALL who have reduced leukemia load after induction therapy and thus a presumably lower risk of CRS. Such studies are underway (Clinical trial information: NCT02101853, NCT02393859).
Twenty-four patients (34%) received alloHSCT as permitted per protocol, including seven who had had a prior transplantation. The data support the feasibility of using blinatumomab-induced T-cell activation in patients with prior alloHSCT, but require †Does not include two deaths caused by disease progression, including one patient who died as a result of recurrent leukemia. These deaths were reported by the investigators as adverse events.
‡Patient died after allogeneic hematopoietic stem-cell transplantation after blinatumomab-induced remission (only one of the patients with multiorgan failure).
further investigation. Reports of compassionate use of blinatumomab in children with relapsed/refractory disease and prior alloHSCT have shown that blinatumomab did not induce or exacerbate graft-versus-host disease.
23,24 B-cell deficiency after chronic, blinatumomab-induced depletion of CD19-positive cells can be managed with immunoglobulin infusions. 25 In our study, analysis of long-term immunoglobulin levels in patients who responded to blinatumomab but did not proceed to alloHSCT, as reported for adults with MRD-positive ALL, 26 is ongoing. Several studies have investigated or are investigating alternative treatments for ALL, including anti-CD22 epratuzumab 27 and inotuzumab ozogamicin.
28 Among CD19-directed approaches, chimeric antigen receptor (CAR) T-cell technology has shown high remission rates in pediatric relapsed/refractory BCP-ALL. Among 30 patients (mainly children) with relapsed/refractory ALL receiving anti-CD19 CAR T cells, 90% achieved CR; however, 27% had severe CRS requiring intensive care up to mechanical ventilation, and . 40% had neurotoxicity. 29, 30 In both CD19-targeted approaches, blinatumomab and CD19 CAR T cells, CD19-negative relapses have been reported. 19, 29 Escape mechanisms likely vary and may include pre-existing CD19-negative clones, or CD19 mutations and/or expression of truncated CD19 from alternatively spliced isoforms, as reported recently for CART-19 epitopes. 31 Future strategies may need to integrate therapies targeting different antigens to circumvent such escape mechanisms.
In summary, we identified the MTD and a recommended dosage for immunotherapy with single-agent blinatumomab in children and adolescents with BCP-ALL who were refractory or in second relapse or who had relapsed after alloHSCT. Blinatumomab showed antileukemic activity across age and risk groups. This study supports further evaluation of blinatumomab in children with BCP-ALL, including those with first-relapse or newly diagnosed disease at high risk of treatment failure because of significant MRD burden or unfavorable cytogenetics. 
